Literature DB >> 16339124

Potential role of interleukin-18 in liver disease associated with insulin resistance.

Abel López-Bermejo1, Montserrat Bosch, Mònica Recasens, Josefina Biarnés, Eduardo Esteve, Roser Casamitjana, Joan Vendrell, Wifredo Ricart, José-Manuel Fernández-Real.   

Abstract

OBJECTIVE: Interleukin (IL)-18 has been associated with obesity and insulin resistance, both risk factors for the development of liver disease, but the role of IL-18 in liver disease associated with insulin resistance is presently unknown. We hypothesized that circulating IL-18 would be related to serum concentrations of liver chemistry tests (LCTs) in apparently healthy subjects and wished to study whether this correlation was dependent on insulin sensitivity (S(I)). RESEARCH METHODS AND PROCEDURES: One hundred six apparently healthy white men consecutively enrolled in a cross-sectional, population-based study dealing with S(I) in men were studied, and S(I) (minimal model analysis), LCTs (colorimetry), and IL-18 serum concentrations (immunoassay) were assessed.
RESULTS: Compared with subjects in the lowest quartile for serum IL-18, subjects in the highest quartile exhibited increased serum triglycerides and decreased S(I), in addition to higher serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (all p < 0.05). The direct association between both ALT and AST and IL-18 was further confirmed by examining the distribution of serum IL-18 by quartiles of ALT and AST. Subjects in the highest quartile for serum ALT and AST had higher IL-18 concentrations compared with subjects in the lowest quartile for these LCTs (both p = 0.01). In multiple regression analysis, IL-18, but not S(I), was an independent predictor of serum concentrations of ALT and AST, explaining 7% and 4% of their variance, respectively. DISCUSSION: In summary, IL-18 serum concentrations are associated in apparently healthy humans with plasma concentrations of various LCTs. IL-18 could contribute to the development of liver disease associated with insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16339124     DOI: 10.1038/oby.2005.237

Source DB:  PubMed          Journal:  Obes Res        ISSN: 1071-7323


  6 in total

Review 1.  Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Sanja Stojsavljević; Marija Gomerčić Palčić; Lucija Virović Jukić; Lea Smirčić Duvnjak; Marko Duvnjak
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

2.  Hepatic expression of inflammatory genes and microRNAs in pigs with high "cholesteryl ester transfer protein" (CETP) activity.

Authors:  Susanna Cirera; Benedicte C Juul Tørsleff; Christian Ritz; Merete Fredholm; Peter M H Heegaard; Kerstin Skovgaard
Journal:  Mamm Genome       Date:  2016-05-30       Impact factor: 2.957

3.  Inhibition of hepatic interleukin-18 production by rosiglitazone in a rat model of nonalcoholic fatty liver disease.

Authors:  Hai-Ning Wang; Yan-Rong Wang; Guo-Qiang Liu; Zhe Liu; Pei-Xian Wu; Xiao-Ling Wei; Tian-Pei Hong
Journal:  World J Gastroenterol       Date:  2008-12-21       Impact factor: 5.742

4.  Adult subjects with Prader-Willi syndrome show more low-grade systemic inflammation than matched obese subjects.

Authors:  A Caixàs; O Giménez-Palop; M Broch; C Vilardell; A Megía; I Simón; G Giménez-Pérez; D Mauricio; J Vendrell; C Richart; J M González-Clemente
Journal:  J Endocrinol Invest       Date:  2008-02       Impact factor: 4.256

5.  Predictive Role of Interleukin-18 in Liver Steatosis in Obese Children.

Authors:  Marta Flisiak-Jackiewicz; Anna Bobrus-Chociej; Eugeniusz Tarasów; Małgorzata Wojtkowska; Irena Białokoz-Kalinowska; Dariusz Marek Lebensztejn
Journal:  Can J Gastroenterol Hepatol       Date:  2018-04-26

6.  A Study to Investigate the Efficacy and Safety of an Anti-Interleukin-18 Monoclonal Antibody in the Treatment of Type 2 Diabetes Mellitus.

Authors:  Elizabeth A McKie; Juliet L Reid; Prafull C Mistry; Stephen L DeWall; Lee Abberley; Philip D Ambery; Blas Gil-Extremera
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.